Harinder Gill

21PUBLICATIONS
49CO-AUTHORS
PharmacogenomicsGene and molecular therapyMedical virologyHaematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Oct 13, 2026
VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.

|Apr 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

|Mar 24, 2026
Ropeginterferon alfa-2b for prefibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction.

Harinder Gill, Lester Au, Rita Lok Hay Yim

|Feb 27, 2026
Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia.

Harinder Gill, Francesca Palandri, David M Ross

|Jul 31, 2025
A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia.

Harinder Gill, Rita Yim, Paul Lee

|Jul 17, 2025
Clinical Practice Recommendations for Myelofibrosis Management in the Asia-Pacific Region: The APAC-MF Alliance.

Keita Kirito, Chul Won Choi, Than Hein

Pageof 4

Frequent Collaborators

7 joint publications

Rita Yim

6 joint publications

Paul Lee

5 joint publications

Lynn Chin

4 joint publications

David M Ross